Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-GR Study of cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in genital and rectal compartments
2021-006779-41Phase 4Completed
- Sponsor
- Frazier Life Sciences
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cabotegravir and rilpivirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Frazier Life Sciences. Started Jul 2022; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2021-006779-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006779-41.